Status:
UNKNOWN
Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma
Lead Sponsor:
Maastricht University Medical Center
Conditions:
Nodular Basal Cell Carcinoma
Eligibility:
All Genders
18-90 years
Phase:
PHASE3
Brief Summary
Basal cell carcinoma (BCC) is a slow-growing, locally invasive malignant epidermal skin tumour. It is the most common malignant disease in Caucasians, representing approximately 80% of all cases of sk...
Eligibility Criteria
Inclusion
- Adults aged 18 years or older
- Primary histologically proven nodular BCC ≥ 4mm and ≤ 20mm in diameter. (If the tumour exhibits additional sBCC characteristics, but also contains nodular component that extend into the reticular dermis, the tumour will be classified as nBCC with superficial components and will be included).
- Comorbidities may not interfere with study treatment
- Capable to understand instructions
Exclusion
- A nodular BCC located in the H-zone of the face or hairy scalp
- Recurrent (previously treated) nBCC
- Aggressive BCC subtypes (morphoea, micronodular, or BCC with squamous differentiation)
- Life expectancy of less than five years
- Breast-feeding or pregnant women
- Serious comorbidities
- Use of immunosuppressive medication during the trial period or within 30 days before enrolment
- Patients with genetic skin cancer disorders
Key Trial Info
Start Date :
January 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
145 Patients enrolled
Trial Details
Trial ID
NCT02242929
Start Date
January 1 2016
End Date
December 1 2022
Last Update
September 24 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maastricht University medical Centre
Maastricht, Limburg, Netherlands, 6202AZ